| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | 35.6% YoY growth this quarter. |
|---|---|
| Margins | Record gross margins of 59.1%; expects 55-56% sustainability. |
| Order book | Order book remains strong across geographies. |
| Demand visibility | Strong order book; softer summer demand in North America noted. |
| Management confidence | High; visibility for doubling revenue within five years. |
Growth
Revenue grew 35.6% YoY to INR841 Cr. PAT surged 173.9% YoY to INR159.4 Cr. EBITDA margin expanded to 25.3%.
Outlook
Guided for FY27 revenue growth of 15-20% and 20-21% EBITDA margin. Target to double revenue in 5 years.
Risks
Geopolitical volatility, shipping hurdles in Middle East, and potential US duty changes are key monitorables.
Last quarter's promises, checked
Delivered
- Guided FY26 Revenue INR 3,000 Cr → delivered INR 2,951 Cr (= BEAT)
- Guided 15-20% Revenue growth → delivered 35.6% (= BEAT)
- Guided 20-21% EBITDA margin → delivered 25.3% (= BEAT)
Partly delivered
- Guided M&A activity in 2027 → delivered QliniQ/ABCnow acquisitions (= PARTIAL)
Investor Presentation filed with BSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹326.05
- Market cap
- ₹14,775 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.6×Sector 47.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Marksans Pharma Q1 FY27 Results: Net Profit ₹159.4 Cr, Up 173.9% YoY
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹159.4 Cr · +173.9% YoY
Marksans Pharma Business Update
Marksans Pharma Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The filing details operational and sustainability metrics.